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Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164 S161vs. 0.15 mg/ml) as analyzed in standard ADCC assays. Thus,
the purging strategy may be beneﬁcial for the development
of graft-engineering strategies to avoid transplantation of
AML-LSC and revitalize autologous stem cell transplantation
in this indication. The in vivo application may possibly open
additional therapeutic avenues in eliminating residual dis-
ease in autologous as well as allogeneic situations.
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Background: The standard of care for patients (pts) with
Hodgkin lymphoma (HL) who are relapsed/refractory (R/R)
to frontline therapy is salvage chemotherapy followed by
autologous stem cell transplant (auto-SCT), with improved
outcomes reported for pts who achieve complete remission
(CR) prior to auto-SCT. Because standard therapies in the ﬁrst
relapse setting produce variable responses (19e60% CR rates)
and are associatedwith signiﬁcant toxicities, new treatments
are needed. Two highly active therapies in the second salvage
setting are the antibody-drug conjugate, brentuximab
vedotin (ADCETRIS) (34% CR; Younes, 2012), and the
bifunctional alkylating agent, bendamustine (33% CR; Mos-
kowitz, 2013). A phase 1/2, single-arm, 2-stage, open-label
study was designed to evaluate the safety and efﬁcacy of
brentuximab vedotin in combination with bendamustine for
treatment of HL in ﬁrst relapse. Interim results from the
phase 1 (safety) cohort are presented.
Methods: Pts receive brentuximab vedotin (1.8 mg/kg, up to
16 cycles), in combinationwith bendamustine (90mg/m2, up
to the ﬁrst 6 cycles). After Cycle 2, hematopoietic stem cells
are mobilized and collected for patients eligible for auto-SCT.
Response is assessed by the investigator per Cheson 2007.
Results: Six HL pts (5 females, 1 male) with a median age of
45 yrs (range, 20 to 61 yrs) have received at least 1 cycle of
brentuximab vedotin in combination with bendamustine.
Five pts are relapsed and 1 pt is primary refractory to front-
line chemotherapy. A median of approximately 16 mos
(range, 8 to 40 mos) have elapsed since the pts’ initial
diagnosis. To date, a maximum of 4 cycles of the combi-
nation regimen have been received and all patients remain
on treatment. Adverse events (AEs) reported for >1 pt are
nausea (4 pts); chills, ﬂushing, lymphopenia, and pyrexia (3
pts each); and constipation, dyspnea and throat tightness
(2 pts each). Three pts have had serious AEs: Gr 1 chills and
pyrexia in 1 pt, infusion-related reactions in 1 pt (Gr 1/2
throat tightness, urticaria, pyrexia, papular rash), and Gr 3
diarrhea (unrelated per the investigator) in 1 pt. Additional
Grade 3 AEs are lymphopenia (3 pts) and generalized rash
and dyspnea (1 pt each). No dose-limiting toxicities have
yet been reported. CR has been achieved in all 5 patients
who have been assessed for response (4 at Cycle 2 and 1 at
Cycle 4).
Conclusions: To date, brentuximab vedotin 1.8 mg/kg
administeredwith bendamustine 90mg/m2 has not exceededthe maximum tolerated dose and enrollment to this cohort is
ongoing. CR has been achieved in all patients who have been
assessed for response. Updated safety and response data, as
well as feasibility of stem cell mobilization and collection, will
be presented at the meeting.231
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Background: The role of allogeneic hematopoietic cell
transplantation (HCT) in multiple myeloma for consolidation
of initial response in the era of novel agents has not been
deﬁned. Therefore, we conducted a phase 2 study of alloge-
neic HCT in MM patients achieving at least very good partial
response (VGPR) after initial therapy.
Methods: Seventeen MM patients with ﬁrst VGPR or com-
plete remission (CR) received allogeneic HCT between 01/
2010 and 04/2013 at Mofﬁtt Cancer Center (NCT 00948922).
Eligible patients were age  60and have suitable HLA-
matched donors. All patients received either bortezomib or
lenalidomide (or both) based induction. Three patients (18%)
underwent autologous HCT with melphalan plus bortezomib
conditioning (MEL 200 plus bortezomib 1.3 mg/m2) after
induction for cytoreduction. Conditioning regimen before
allogeneic HCT consisted of ﬂudarabine 30 mg/m2 x 4 days
and melphalan 70 mg/m2 x 2 days followed by bortezomib
1.3 mg/m2 (Flu/Mel/Vel). GVHD prophylaxis was tacrolimus
plus either methotrexate (n¼9), or mycophenolate mofetil
(n¼4), or sirolimus (n¼4). No maintenance therapy was
prescribed.
Results: The median age at transplant was 51 (25 e 57)
years. Seven patients (41%) have high-risk cytogenetics/
FISH. Disease status at the time of allogeneic HCT was VGPR
(n¼8), CR (n¼3), or stringent CR (n¼6). All patients received
unmanipulated peripheral blood stem cell grafts from HLA-
matched sibling donors (n¼7) or 8/8 HLA-matched unre-
lated donors (n¼10). Neutrophil engraftment was achieved
at a median of 14 (11 - 18) days and platelet engraftment
with a median of 17 (13 - 21) days. Best responses after
allogeneic HCT were CR (n¼2), sCR (n¼13), and disease
progression (n¼2). The 2-year progression-free survival es-
timate is 80% (95%CI: 51 e 98) for standard-risk and 51%
(95%CI: 15 e 87) for high-risk, respectively. With a median
follow up of 18 (3 - 43) months, the 2-year overall survival
estimate is 88% (95%CI: 68 e 99). The cumulative incidence
of non-relapse mortality was 6% (95%CI: 0.0 e 22) at 100
days and 13% (95%CI: 1 e 34) at 1 year, respectively. The
cumulative incidence of grades 2-4 acute GVHD at day 100
was 41% (95% CI: 20 e 65) and the cumulative incidence of
moderate to severe chronic GVHD at 1 year was 8.0% (95%
CI: 0.0 e 29).
Conclusions: These results indicate that allogeneic HCT for
MM in VGPR or CR as consolidation achieves favorable dis-
ease control. The study is ongoing to assess long-term safety
of this modality. Amulticenter trial is planned to evaluate the
utility of allogeneic HCT in high-risk MM.
